期刊
CIRCULATION-CARDIOVASCULAR INTERVENTIONS
卷 3, 期 5, 页码 408-U39出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCINTERVENTIONS.109.904425
关键词
myocardial infarction; MRI; angioplasty
Background-Erythropoietin improves myocardial function in experimental models of myocardial infarction. The aim of the present study was to determine the value of erythropoietin in patients with acute ST-elevation myocardial infarction. Methods and Results-This randomized, double-blind study included 138 patients admitted with acute ST-elevation myocardial infarction and treated with primary percutaneous coronary intervention. Patients were randomly assigned to receive epoetin-beta (3.33x104 U, n = 68) or placebo (n = 70) immediately and at 24 and 48 hours after percutaneous coronary intervention. The primary end point was left ventricular ejection fraction after 6 months measured by MRI. Other end points included infarct size at 5 days and 6 months. Clinical adverse events (death, recurrent myocardial infarction, stroke, and infarct-related artery revascularization) were investigated at 30 days and 6 months. Left ventricular ejection fraction at 6-month follow-up was 52.0 +/- 9.1% in the erythropoietin group compared with 51.8 +/- 9.3% in the placebo group (P = 0.92). Five days after percutaneous coronary intervention, left ventricular ejection fraction was 49.4 +/- 8.0% in the erythropoietin group and 50.8 +/- 7.3% in the placebo group (P = 0.32); infarct size was (P = 0.27). The cumulative 6-month incidence of death, recurrent myocardial infarction, stroke or target vessel revascularization was 13.2% in the erythropoietin group and 5.7% in the placebo group (hazard ratio, 2.36; 95% confidence interval, 0.73 to 7.66; P = 0.15). Conclusions-In patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention, erythropoietin treatment did not improve left ventricular ejection fraction or reduce infarct size but may increase clinical adverse events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据